Pfizer/BioNTech to seek emergency use approval for virus vaccine Friday

Marco Green
November 21, 2020

Pfizer and its partner BioNTech confirmed they will apply Friday for emergency use authorization for their coronavirus vaccine, becoming the first to do so in the U.S. as the pandemic rages around the world.

Just a week after Pfizer and BioNTech said their vaccine was over 90% effective, Moderna has published an early analysis of it's trial.

The announcement also confirms what BioNTech's CEO told AFP Thursday.

Indian government is in dialogue with U.S. biotech giant Moderna, regarding initial successful development of its COVID-19 vaccine candidate, which the drugmaker on Monday announced had achieved 94.5 per cent efficacy in phase 3 trials.

U.S. company Moderna plans to apply for approval for it's vaccine in the coming weeks.

The official added that the European Union will pay 10 euros a pop for 225 million doses of CureVac's vaccine candidate, down from 12 euros per shot price tag which the company initially suggested.

The Food and Drug Administration has not said how long it will take to study the vaccine data, but the government expects to give the green light for the vaccine in the first two weeks of December.

The news sent Moderna stock soaring 8 per cent when stock markets opened on Monday but it was also a badly needed shot in the arm for the stock market overall, on hopes that the pandemic could be closer to its end than to its beginning.

If Reuters' information is confirmed, the combined CureVac and Pfizer-BioNTech vaccine dose numbers would total between 425 million and 705 million doses, with the latter figure being more than enough to vaccinate every single man, woman and child in the bloc.

The extraordinary results have sparked euphoria as the unprecedented compression of vaccine development timelines from years to months looks to be paying off.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER